Compare iShares MBS ETF (MBB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs TransMedics Group Inc — how do they compare? iShares MBS ETF trades at $89.75 (market cap $35.41B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: iShares MBS ETF is far larger — about 12.9× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 5,388,525). Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and TransMedics Group Inc for 24 Days on average.
| MBB | TMDX | |
|---|---|---|
Market Cap | $35.41B | $2.74B |
Volume | 5,388,525 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $150.42 |
52-Week Low | $89.09 | $61.99 |
Typical Hold Time | 96 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.68, up 0.52% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock recently hit a new 52-week low of $91.02 on September 15, 2026, as short interest surged 98.3% in September, reflecting negative sentiment. Recent news highlights concerns over rising intermediate-term rates and inflation pressures impacting mortgage-backed securities.
The outlook remains cautious due to interest rate sensitivity and convexity risks in the mortgage market. While institutional buying by firms like Corient Private Wealth provides some support, the bearish technicals and macroeconomic headwinds suggest limited near-term upside. Key risks include further rate hikes and prepayment volatility in the MBS portfolio.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
